drugset / Trial / NCT01067365
Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.
Timeline
- Start
- 2006-03
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Androxal | Unknown | 12.5 mg | Oral |
| Subject | Androxal | Unknown | 25 mg | Oral |